JAK2 Mutation May Predict Response and Guide First Line Treatment in Rheumatoid Arthritis

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT04667988

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:37:54.211325+00:00

Published At

2020-12-16T00:00:00+00:00

Record Updated At

2020-12-16

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Response Assessment in Newly Diagnosed RA Patients at 3rd Month Was Evaluated by DAS28 and ACR in Relation to JAK Expression"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2020-12-16"

protocolSection.identificationModule.nctId

"NCT04667988"

protocolSection.identificationModule.officialTitle

"JAK2 Mutation May Predict Response and Guide First Line Treatment in Rheumatoid Arthritis"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["NA"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Response Assessment in Newly Diagnosed RA Patients at 3rd Month Was Evaluated by DAS28 and ACR in Relation to JAK Expression (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.